Issued: Monday 8 September 2008, London UK
GlaxoSmithKline plc - Directorate change
GlaxoSmithKline plc (GSK) today announced that Chris Viehbacher, Executive Director and President North American Pharmaceuticals, has decided to stand down from the Board on 8th September, and will leave the company with effect from 1st December 2008 to pursue another opportunity.
Andrew Witty, Chief Executive Officer said: I would like to thank Chris for his significant contribution to GSK, he is one of the most talented and respected executives in this industry and we wish him well in his future endeavours."
GlaxoSmithKline - one of the world's leading research-based pharmaceutical and healthcare companies - is committed to improving the quality of human life by enabling people to do more, feel better and live longer. For further information please visit www.gsk.com
Enquiries: |
|
|
UK Media enquiries: |
Philip Thomson |
(020) 8047 5502 |
|
Claire Brough |
(020) 8047 5502 |
|
Alice Hunt |
(020) 8047 5502 |
|
Gwenan White |
(020) 8047 5502 |
|
|
|
US Media enquiries: |
Nancy Pekarek |
(215) 751 7709 |
|
Mary Anne Rhyne |
(919) 483 2839 |
|
Sarah Alspach |
(215) 751 7709 |
|
|
|
European Analyst/Investor enquiries: |
David Mawdsley |
(020) 8047 5564 |
|
Sally Ferguson |
(020) 8047 5543 |
|
Gary Davies |
(020) 8047 5503 |
|
|
|
US Analyst/ Investor enquiries: |
Frank Murdolo |
(215) 751 7002 |
|
Tom Curry |
(215) 751 5419 |
Cautionary statement regarding forward-looking statements |
Registered in England & Wales: No. 3888792 |
|
Registered Office: 980 Great West Road Brentford, Middlesex TW8 9GS |